摘要
为研究树突状细胞和细胞因子诱导的杀伤细胞(CIK)为效应细胞的过继免疫联合化疗治疗多发性骨髓瘤(MM)的临床疗效及对患者外周血T细胞亚群、CD4+CD25+调节性T(Treg)细胞的影响,探讨以上治疗对MM患者的细胞免疫调节功能。将36例MM患者随机分为两组:化疗组18例,给予合适的化疗方案;联合组18例,除接受适合的化疗外,还给予DC/CIK免疫治疗,比较两组患者的临床疗效及外周血T细胞亚群、CD4+CD25+调节性T(Treg)细胞比例。结果显示,3周期治疗后,联合组患者的生活质量和临床疗效均比化疗组患者显著提高(P<0.05)。联合组CD3+CD8+比例、CD4+CD25+/CD4+、CD4+CD25+FoxP3+/CD4+CD25+比值均明显低于化疗组(P<0.05);CD3+CD4+/CD3+CD8+比值明显高于化疗组(P<0.05),提示联合治疗组对MM具有更有效的免疫调节功能。研究结果表明DC/CIK免疫治疗联合化疗治疗MM有良好的临床疗效和应用价值,可能是通过免疫调节使MM患者Th2向Th1逆转,从而增强机体抗肿瘤效应的。
To evaluate the treatment value of chemotherapy for patients with multiple myeloma（MM）who undergo adoptive immunotherapy（dendritic cells plus CIK,DC-CIK）and to explore the underline mechanism.The enrolled thirty-six patients with MM were randomly divided into two groups：18patients of group A were treated with DC-DIK alone and another 18 patients of the group B received chemotherapy in addition to DC-CIK.The clinical outcome and peripheral T-lymphocyte subsets and CD4＋CD25Treg were compared between the two groups.by analyzing of The results showed that,at the end of treatment,the efficacy of group B was superior than that of group A in terms of life quality,clinical index and amount of survivals（P〈0.05）.The proportion of CD3＋CD8＋,the ratios of CD4＋CD25＋/CD4＋,CD4＋CD25＋FoxP3＋/CD4＋CD25＋were significantly lower than group A（P〈0.05）,whereas the ratio of CD3＋CD4＋/CD3＋CD8＋were higher than A.These results suggest that DC-CIK combined with chemotherapy could be an effective and promising therapy for patients with MM,and it may attribute to strengthening of the anti-tumor action of bodies by regulating the balance between Th1 and Th2reaction.
出处
《现代免疫学》
CAS
CSCD
北大核心
2015年第2期130-135,共6页
Current Immunology
作者简介
赵霞（1981-），女，主治医师。博士生，主要从事血液病的治疗及研究、间充质干细胞治疗血液病的研究
通讯作者：路希敬（E-mail：18054618175@163．com）
